Funding, M&A, exec moves and hiring — matched to your market, with the people to call.See plans →
Tybr Health Secures $30 Million Series A Financing Led By Vensana Capital To Expand Access To Its B3 Gel® System. announced it raised $30 Million in an initial filing from an offering of $30 Million
PRIVATEJul 21, 2026•19 days ago
Amount Raised
$30 Million
Round Type
Series A
HoustonBiotechnologyHealthcareInvestors
Neovate Capital PartnersMutual Capital PartnersVensana Capital
Description
TYBR Health announced a $30 million Series A financing led by Vensana Capital and Mutual Capital Partners, with participation from Neovate Capital Partners and existing investors. The funds will be utilized to expand commercial access to the FDA-cleared B3 GEL® System and broaden its product indications. It will also support clinical studies evaluating tissue protection during orthopedic surgery. This financing aims to improve patient recovery through enhanced healing technologies.
Related People
Suggested for you
2 contactsVerified contactsFrida M., Biomedical Engineer
Funding Insights
Based on industry dataTypical timeline to Series B
Series A companies typically raise their next round in 10-18 months
Monthly burn rate benchmark
47% of Series A startups spend $400k or more per month on operations
VC-backed spending patterns
VC-backed companies spend 89% more on sales and 100% more on marketing than bootstrapped peers
Tech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech